Alzheimer's Research & Therapy | Most Viewed

Submit a manuscript Register

Explore journal

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
	1. 5316 Accesses	Research Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad, Frank Tennigkeit Alzheimer's Research & Therapy 2010, 2:24 (26 August 2010) Abstract \| Full text \| PDF \| PubMed
	2. 4988 Accesses	Research Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:2 (23 February 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Baseline cognitive assessments of probable Alzheimer’s disease patients can help predict future performance in cognition and activities of daily living, and should be considered when designing clinical trials in Alzheimer’s disease.
	3. 4457 Accesses	Research A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease Sebastian Palmqvist, Lennart Minthon, Carina Wattmo, Elisabet Londos, Oskar Hansson Alzheimer's Research & Therapy 2010, 2:29 (15 October 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A Quick Test of cognitive speed is twice as sensitive as the mini-mental state examination in evaluating cholinesterase inhibitor treatment in Alzheimer’s disease patients, indicating its potential usefulness in the primary care setting.
	4. 4333 Accesses	Research Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease Guriqbal S Basi, Susanna Hemphill, Elizabeth F Brigham, Anna Liao, Danielle L Aubele, Jeanne Baker, Robin Barbour, Michael Bova, Xiao-Hua Chen, Michael S Dappen, Tovah Eichenbaum, Erich Goldbach, Jon Hawkinson, Rose Lawler-Herbold, Kang Hu, Terence Hui, Jacek J Jagodzinski, Pamela S Keim, Dora Kholodenko, Lee H Latimer, Mike Lee, Jennifer Marugg, Matthew N Mattson, Scott McCauley, James L Miller, Ruth Motter, Linda Mutter, Martin L Neitzel, Huifang Ni, Lan Nguyen Alzheimer's Research & Therapy 2010, 2:36 (29 December 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary An amyloid precursor protein selective gamma-secretase inhibitor demonstrates selectivity for inhibiting Amyloid beta production in Alzheimer’s disease transgenic mice and needs to be corroborated in wild-type mice.
	5. 4194 Accesses	Research Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy, Olivier Hermine Alzheimer's Research & Therapy 2011, 3:16 (19 April 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The selective oral tyrosine kinase inhibitor, masitinib, administered as an adjunctive therapy, slows the rate of cognitive decline in Alzheimer’s disease (AD) although further studies are needed to investigate its efficacy and safety.
	6. 3924 Accesses	Research Predictors of long-term cognitive outcome in Alzheimer's disease Carina Wattmo, Åsa K Wallin, Elisabet Londos, Lennart Minthon Alzheimer's Research & Therapy 2011, 3:23 (20 July 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Clinical predictors of a more favorable longitudinal outcome in Alzheimer's disease include male gender, older age, absence of the apolipoprotein E e4 allele, treatment with non-steroidal anti-inflammatory drugs or a higher mean dose of cholinesterase inhibitor.
	7. 3851 Accesses	Review The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Kerensa Broersen, Frederic Rousseau, Joost Schymkowitz Alzheimer's Research & Therapy 2010, 2:12 (14 July 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta has been identified as neurotoxic in patients with Alzheimer’s disease (AD), but we must take into account its structural characteristics, as well as size, when exploring AD development.
	8. 3835 Accesses	Review Can aerobic exercise protect against dementia? Neill R Graff-Radford Alzheimer's Research & Therapy 2011, 3:6 (28 February 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Aerobic exercise may be protective of brain health according to recent basic research and epidemiological studies, but prospective blinded studies are needed to evaluate its role in protecting against dementia.
	9. 3818 Accesses	Review Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy Elina Zotova, James AR Nicoll, Raj Kalaria, Clive Holmes, Delphine Boche Alzheimers Res Ther 2010, 2:1 (22 January 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Zotova et al. review the immune processes involved in Alzheimer’s disease pathogenesis and highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies.
	10. 3775 Accesses	Research Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley, Li-Ru Zhao Alzheimer's Research & Therapy 2011, 3:8 (15 March 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stem cell factor and granulocyte-colony stimulating factor limit beta-amyloid accumulation in a mouse model suggesting treatment with hematopoeitic growth factors may offer a new therapeutic approach for Alzheimer’s disease.
	11. 3514 Accesses	Research Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study Jonathan H Williams, Gordon K Wilcock, Jeffrey Seeburger, Aimee Dallob, Omar Laterza, William Potter, A David Smith Alzheimer's Research & Therapy 2011, 3:5 (17 February 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Levels of cerebrospinal fluid (CSF) beta amyloid and tau show non-linear relationships with cognitive scores, with more work necessary to be able to predict Alzheimer’s disease and monitor its progression.
	12. 3365 Accesses	Review Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity Anne Eckert, Karen Schmitt, Jürgen Götz Alzheimer's Research & Therapy 2011, 3:15 (5 May 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Götz and colleagues review the critical role of mitochondria and the close interrelationship of this organelle with the two main pathological features in the pathogenic process underlying Alzheimer’s disease (AD).
	13. 3178 Accesses	Research CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques Eloise H Kok, Teemu Luoto, Satu Haikonen, Sirkka Goebeler, Hannu Haapasalo, Pekka J Karhunen Alzheimer's Research & Therapy 2011, 3:12 (5 April 2011) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary CLU, CR1 and PICALM genes are not strongly related to senile plaque prevalence, or at all to neurofibrillary tangles, and most likely do not affect the development of these Alzheimer’s disease (AD) lesions.
	14. 2821 Accesses	Research Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease Steven H Ferris, Frederick A Schmitt, Judith Saxton, Sharon Richardson, Joan Mackell, Yijun Sun, Yikang Xu Alzheimer's Research & Therapy 2011, 3:22 (20 June 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Increasing the dose of donepezil to 23 mg/d may provide language benefits in patients with moderate to severe Alzheimer’s disease (AD), for whom preservation of language abilities is especially critical.
	15. 2760 Accesses	Review Genetics of Alzheimer disease in the pre- and post-GWAS era Nilüfer Ertekin-Taner Alzheimer's Research & Therapy 2010, 2:3 (5 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ertekin-Taner summarises genetic studies preceding the genome-wide association study (GWAS) era and discusses insights into genetics of Alzheimer’s following recent GWAS results, which may translate into future therapies.
	16. 2693 Accesses	Review Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND) Blossom CM Stephan, Fiona E Matthews, Kay-Tee Khaw, Carole Dufouil, Carol Brayne Alzheimers Res Ther 2009, 1:4 (9 July 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stephan et al. review the concept of ‘vascular cognitive impairment, no dementia’ (VCIND) and its application for screening individuals at increased risk of dementia secondary to vascular disease and its risk factors.
	17. 2605 Accesses	Commentary Mild traumatic brain injury: a risk factor for neurodegeneration Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski, Ann C McKee Alzheimer's Research & Therapy 2010, 2:18 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary Head trauma can lead to progressive neurodegeneration and further study of this risk factor could help us improve prevention and treatment strategies for other neurodegenerative diseases.
	18. 2436 Accesses	Research For debate: substituting placebo controls in long-term Alzheimer's prevention trials René Spiegel, Manfred Berres, André R Miserez, Andreas U Monsch, the Alzheimer's Disease Neuroimaging Initiative Alzheimer's Research & Therapy 2011, 3:9 (21 March 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A novel clinical study design, which uses mathematical models to forecast outcomes, may complement forthcoming long-term, randomized Alzheimer’s disease drug studies and remove the need for placebo controls.
	19. 2303 Accesses	Research Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice Vjera A Holthoff, Steven Ferris, Ralf Ihl, Philippe Robert, Bengt Winblad, Serge Gauthier, Kati Sternberg, Frank Tennigkeit Alzheimer's Research & Therapy 2011, 3:27 (14 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The Relevant Outcome Scale for Alzheimer's disease (ROSA) is a valid and reliable instrument to aid medical practitioners in the routine assessment of the severity of Alzheimer's disease symptoms and disease progression.
	20. 2029 Accesses	Review Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease Roy O Weller, Stephen D Preston, Malavika Subash, Roxana O Carare Alzheimer's Research & Therapy 2009, 1:6 (12 October 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Weller et al. highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies for Alzheimer's disease.
	21. 2006 Accesses	Review Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications Robert Laforce, Gil D Rabinovici Alzheimer's Research & Therapy 2011, 3:31 (10 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Potential clinical applications of amyloid positron emission tomography (PET) and its role in the differential diagnosis of a range of neurodegenerative conditions are reviewed by Laforce and Rabinovici.
	22. 1867 Accesses	Review Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease Randall J Bateman, Paul S Aisen, Bart De Strooper, Nick C Fox, Cynthia A Lemere, John M Ringman, Stephen Salloway, Reisa A Sperling, Manfred Windisch, Chengjie Xiong Alzheimer's Research & Therapy 2011, 3:1 (6 January 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Trials in autosomal-dominant Alzheimer’s disease (ADAD) are important in order for us to study individuals destined to develop the clinical disease and may yield breakthroughs in the treatment of sporadic AD.
	23. 1818 Accesses	Review Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions Larry G Brooks, David A Loewenstein Alzheimer's Research & Therapy 2010, 2:28 (29 September 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary From mild cognitive impairment through to dementia, Alzheimer’s disease is a continuous process and it is likely that multivariate models incorporating cognitive measures, functional variables and biomarker data are best suited to assess this longitudinal change.
	24. 1737 Accesses	Review Role of structural MRI in Alzheimer's disease Prashanthi Vemuri, Clifford R Jack Alzheimer's Research & Therapy 2010, 2:23 (31 August 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Structural MRI (sMRI) plays many roles as an Alzheimer’s disease (AD) biomarker and is of both prognostic and diagnostic value, but further work is needed in order to integrate it with other clinical measures.
	25. 1731 Accesses	Research Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Samina Siddiqui, Rachelle S Doody Alzheimers Res Ther 2009, 1:7 (21 October 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Persistent treatment with cholinesterase inhibitors and/or memantine had a positive impact on Alzheimers disease (AD) progression by multiple cognitive and functional outcome measures.